Fortress Biotech, Inc. — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 42/100
What the filing says
Fortress reported Q2 2026 net revenue of $18.7M (up 14% YoY), with consolidated cash rising to $196.6M from $79.4M at year-end 2025, primarily driven by a $205M Priority Review Voucher (PRV) sale in Q1 2026. Key portfolio developments include Crystalys Therapeutics securing $130M Series B funding for dotinurad (on which Fortress subsidiary Urica holds 3% royalty), Journey Medical expanding Emrosi payer access to 150M+ commercial lives (85% of U.S. market), and early royalty generation from ZYCUBO and UNLOXCYT launches. Q2 net loss attributable to common stockholders was $(2.5)M or $(0.08)/share, versus $13.4M profit ($0.50/share) in Q2 2025; six-month net income of $109.9M reflects the one-time PRV gain.
Why this rating
PRV sale ($205M) is 469% of market cap—transformational for cash position. Organic revenue growth modest (14%), operations remain loss-making. Royalty streams nascent. Moderate near-term trajectory benefit, but sustainability unclear.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.